Protalix at Morgan Stanley conference: rare-disease growth in focus

Protalix reported first-half 2026 revenue of $53.6 million, including a $25 million regulatory milestone, and net income of $22.1 million versus a $3.5 million loss a year earlier. The company reaffirmed 2026 revenue guidance of $78 million-$83 million, including Elfabrio revenue of $33 million-$35 million, or roughly 50% growth from 2025, supported by new four-week dosing approvals in Europe and the U.K. Elfabrio's U.S. patent protection was extended through November 2035, while the longer-term PRX-115 gout catalyst remains dependent on phase 2 topline data expected in the second half of 2027. Protalix ended the quarter with about $41 million of cash and no debt, though revenue may remain quarterly volatile because of partner inventory purchasing patterns.

Analysis

PLX’s investable near-term thesis is not the 2027 gout readout; it is whether the market begins to capitalize recurring Elfabrio economics rather than treating reported batch shipments as a volatile microcap biotech revenue line. The key modeling issue is that 2026 profitability is flattered by a non-recurring payment, while the guided operating base implies a materially smaller recurring revenue pool. Consequently, a weak quarterly print caused by Chiesi inventory normalization could create an attractive entry rather than invalidate the commercial trajectory—provided full-year Elfabrio guidance is retained.

The four-week European regimen improves switching economics, but it also creates a subtle offset: fewer infusions can reduce drug utilization per patient depending on dose equivalence and reimbursement mechanics. The commercial benefit therefore must show up in net patient additions and/or price realization, not merely regimen conversion. Chiesi’s private ownership leaves PLX investors structurally information-disadvantaged, likely preserving a liquidity/visibility discount until management supplies patient, territory, or order-backlog KPIs. U.S. regimen approval is the highest-value 6-18 month commercial catalyst, but timing and FDA requirements are unknown.

PRX-115 should be assigned limited value before phase 2 because the relevant hurdle is not urate lowering alone: it must demonstrate durability, safety/immunogenicity, and clinically credible convenience versus KRYSTEXXA, potentially without methotrexate. A differentiated entrant would pressure AMGN only at the margin and only after a multi-year development and launch cycle; AMGN’s established prescriber access and payer contracts remain the central competitive barrier. The contrarian point is that PLX may be cheap on normalized commercial cash flow, but the apparent low earnings multiple is not meaningful if investors annualize the milestone-driven first half.

Over the next 1-3 months, watch for confirmation of annual Elfabrio guidance and evidence that European reimbursement rollouts translate into orders. Over 6-18 months, FDA engagement on U.S. monthly dosing and sustained cash generation without dilution matter more than discovery-stage pipeline commentary. Thesis breaks on reduced Elfabrio guidance, cash burn that brings financing forward of PRX-115 data, or evidence that less frequent dosing dilutes revenue per patient faster than it improves share.

Key Decisions for Investors

• Accumulate PLX only on shipment-driven volatility below $2.30-$2.40, rather than chase conference promotion; target $3.10-$3.50 over 6-12 months if annual Elfabrio guidance is reaffirmed and cash remains stable. Exit/reassess if 2026 Elfabrio guidance falls below $33M or cash declines materially without a clear working-capital explanation.
• Treat the next PLX earnings release as a KPI event: require disclosure or credible directional evidence on Elfabrio patients, European country reimbursement, and Chiesi purchase visibility. A quarterly revenue miss with maintained annual guidance is a buy-the-dislocation setup; a guidance cut is not.
• Do not position in AMGN on PRX-115 headlines. Revisit a modest AMGN/PLX relative-value short AMGN versus long PLX only after phase 2 demonstrates durable urate control with a clearly superior dosing or immunomodulator profile; that catalyst is H2 2027, not current.
• Avoid underwriting PRX-115 in base-case PLX valuation until phase 2. Use pre-data position sizing consistent with binary clinical risk, and consider trimming any speculative run above $3.20 absent new commercial KPIs or a disclosed FDA regulatory path.